Lion Biotechnologies Announces 5-Year Extension of National

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 24, 2016 at 6:00 PM

Lion Biotechnologies Announces 5-Year Extension of National Cancer Institute CRADA for Development of Novel TIL Immuno-Oncology Therapies

NEW YORK, NY --(Marketwired - August 24, 2016) - Lion Biotechnologies, Inc. ( NASDAQ : LBIO ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced an amendment of its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to extend the CRADA for an additional five-year term until 2021. Under the extended CRADA, the Company will continue working with Steven A. Rosenberg, M.D., Ph.D., chief of NCI's Surgery Branch, to develop TIL which have not been genetically altered as a stand-alone therapy or in combination with FDA-licensed products routinely used for treatment of the indications covered under the CRADA. The CRADA includes the development of TIL therapy for the treatment of metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Under the CRADA, combination of TIL with FDA-approved drugs, such as checkpoint inhibitors, will be explored. The financial terms of CRADA were not changed.

"We continue to explore the potential utility of the TIL technology in treating multiple solid tumor indications in our commitment to offer TIL to patients. The amendment to the CRADA provides for further investigation of TIL in multiple indications as single regimen as well as in combination with other FDA-approved therapies, such as checkpoint inhibitors. The collaboration includes development of methods for generation and selection of TIL in the noted indications and clinical trials. We are excited to continue our strong working relationship with Dr. Rosenberg and NCI in developing TIL therapy for patients," said Maria Fardis, PhD, MBA, Lion Biotechnologies President and Chief Executive Officer.

The CRADA, originally entered into in August 2011 for the development of TIL therapy in the treatment of metastatic melanoma, was previously amended in January 2015, to increase its annual funding and to include four additional indications.

About Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. TIL therapy is also being evaluated in clinical trials at the National Cancer Institute, MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com .

Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's future goals, its operating and financial performance, additional studies and product development, expansion of the company's research platform, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections. Risks and uncertainties include, but are not limited to, risks related to the research and development conducted under the amended CRADA. A further list and description of these and other risks, uncertainties and other factors can be found in Lion Biotechnologies, Inc. most recent Annual Report on Form 10-K and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.lionbio.com . Any forward-looking statement made in this release speaks only as of the date of this release. Lion Biotechnologies, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Investor Contact: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media Contact: Alex Ferrara inVentivHealth Public Relations 212-849-9487 Alexandra.Ferrara@inventivhealth.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Melt Expands with Key Texas Franchise Deal

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Nonprofit and Partners Gift Homes to Veterans

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

AI Deception Challenges the Confidence of Fraud Defenses

Fraud Week Spotlights AI Deception Alright, here's the rub: we're in Fraud Week 2026, and boy, is AI shaking the foundations of yesterday's fraud defenses! With all this AI talk, you would expect systems to be near invincible by now. But reality? A different beast altogether. AI has this knack of tripling up the complexity while pretending to solve it, making traditional...

Wiz Khalifa Ignites MJBizCon 2026 with Keynote and Music

An Icon in Cannabis Culture Hits the Stage When you mix business with pleasure, you get something like what MJBizCon's cooking up this year. Wiz Khalifa, the man with a knack for turning passion into profit, is jumping onto the stage—not just as a performer, but also as a keynote speaker. On December 2, attendees are in for a treat as he steps into a new spotlight at...

Choosing the Right Pressure-Treated Lumber for Projects

Diving into the World of Pressure-Treated Lumber John Michael Nixa, the go-to expert from West Side Lumber, has dropped some real nuggets in the world of pressure-treated lumber. This isn't some clickbait headline; it's about making sure your deck or fence doesn't fall apart after the first thunderstorm. Understanding the Lumber Treatment Now, before you run off to the...

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

Pine AI Unveils AI Studio & Real-World Call Feature

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Anderson University Sees Financial Turnaround Success

Anderson University, against all odds, is shaking up the financial narrative they’ve been stuck in for a while. It’s kind of like finding a $20 bill in an old coat—a nice surprise but it doesn’t happen every day. The university’s recent report on their financial progress is reminding folks that when it comes to fiscal discipline, sometimes you just need fresh...

Fluence Energy Faces Class Action: Investor Insights

Investor Blues: Fluence Under the Weather If you've been keeping an eye on Fluence Energy (NASDAQ:FLNC), you're probably clutching your metaphorical pearls right now. Here's the scoop: on November 2, 2026, the stock took another nosedive—dropping nearly 9%—as the company announced that both CEO Julian Nebreda and CFO Ahmad Pasha had packed their bags. A leadership...